CA2893318A1 - Thienopyridine derivatives for the treatment and prevention of dengue virus infections - Google Patents

Thienopyridine derivatives for the treatment and prevention of dengue virus infections Download PDF

Info

Publication number
CA2893318A1
CA2893318A1 CA2893318A CA2893318A CA2893318A1 CA 2893318 A1 CA2893318 A1 CA 2893318A1 CA 2893318 A CA2893318 A CA 2893318A CA 2893318 A CA2893318 A CA 2893318A CA 2893318 A1 CA2893318 A1 CA 2893318A1
Authority
CA
Canada
Prior art keywords
amino
thieno
pyridine
carboxamide
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2893318A
Other languages
English (en)
French (fr)
Inventor
Dongcheng Dai
James R. Burgeson
Shanthakumar R. Tyavanagimatt
Chelsea M. Byrd
Dennis E. Hruby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siga Technologies Inc
Original Assignee
Siga Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/708,224 external-priority patent/US20130129677A1/en
Application filed by Siga Technologies Inc filed Critical Siga Technologies Inc
Publication of CA2893318A1 publication Critical patent/CA2893318A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/22Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2893318A 2012-12-07 2013-12-06 Thienopyridine derivatives for the treatment and prevention of dengue virus infections Abandoned CA2893318A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/708,224 2012-12-07
US13/708,224 US20130129677A1 (en) 2009-02-27 2012-12-07 Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections
PCT/US2013/073449 WO2014089378A1 (en) 2012-12-07 2013-12-06 Thienopyridine derivatives for the treatment and prevention of dengue virus infections

Publications (1)

Publication Number Publication Date
CA2893318A1 true CA2893318A1 (en) 2014-06-12

Family

ID=50884015

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2893318A Abandoned CA2893318A1 (en) 2012-12-07 2013-12-06 Thienopyridine derivatives for the treatment and prevention of dengue virus infections

Country Status (4)

Country Link
EP (1) EP2928470A4 (enrdf_load_stackoverflow)
JP (1) JP2016501883A (enrdf_load_stackoverflow)
CA (1) CA2893318A1 (enrdf_load_stackoverflow)
WO (1) WO2014089378A1 (enrdf_load_stackoverflow)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105418635A (zh) * 2015-12-25 2016-03-23 上海应用技术学院 一种噻吩并吡啶类医药中间体的合成方法
CN105769866B (zh) * 2016-03-31 2018-05-04 南通江海港建设工程有限公司 一种化合物在增加血小板浓度药物中的用途
CN105832734B (zh) * 2016-03-31 2018-05-04 南通江海港建设工程有限公司 一种化合物在增加血小板浓度药物中的用途
JP7041877B2 (ja) * 2016-06-14 2022-03-25 国立大学法人 東京大学 チエノ[2,3-b]ピリジン誘導体およびキノリン誘導体ならびにそれらの使用
EP3704126A4 (en) 2017-11-03 2020-12-09 Université de Montréal COMPOUNDS AND THEIR USE IN THE EXPANSION OF STEM CELLS AND / OR PROGENITOR CELLS
JP7445609B2 (ja) * 2018-06-06 2024-03-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Epac阻害剤としてのチエノ[2,3-b]ピリジン誘導体及びその医薬用途
WO2021035258A1 (en) * 2019-08-21 2021-02-25 The Scripps Research Institute Bicyclic agonists of stimulator of interferon genes sting
CN111072463A (zh) * 2019-12-03 2020-04-28 辽宁凯莱英医药化学有限公司 一种4-乙氧基-1,1,1-三氟-3-丁烯-2-酮的连续化合成方法
WO2021108999A1 (zh) * 2019-12-03 2021-06-10 辽宁凯莱英医药化学有限公司 一种4-乙氧基-1,1,1-三氟-3-丁烯-2-酮的连续化合成方法
WO2021250231A1 (en) * 2020-06-12 2021-12-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Thienopyridine derivatives for use in the treatment of coronavirus infection
WO2022094816A1 (en) * 2020-11-04 2022-05-12 Janssen Pharmaceuticals, Inc. Solid formulation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0785193A4 (en) * 1994-09-22 2000-04-19 Rational Drug Design Lab ARYLTHIADIAZOLE DERIVATIVES AND ANTIVIRAL PRODUCTS CONTAINING THEM
GB9717576D0 (en) * 1997-08-19 1997-10-22 Xenova Ltd Pharmaceutical compounds
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
US7202363B2 (en) * 2003-07-24 2007-04-10 Abbott Laboratories Thienopyridine and furopyridine kinase inhibitors
AR048669A1 (es) * 2004-03-03 2006-05-17 Syngenta Ltd Derivados biciclicos de bisamida
SE0403171D0 (sv) * 2004-12-23 2004-12-23 Astrazeneca Ab New compounds
JP2006298909A (ja) * 2005-03-25 2006-11-02 Tanabe Seiyaku Co Ltd 医薬組成物
JP2009537551A (ja) * 2006-05-17 2009-10-29 アメリカ合衆国 ホルモン受容体を調節するためのピリミジン低分子量リガンド
US20130129677A1 (en) * 2009-02-27 2013-05-23 Siga Technologies, Inc. Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections
EP2400845B1 (en) * 2009-02-27 2017-02-22 Siga Technologies, Inc. Thienopyridine derivatives for the treatment and prevention of dengue virus infections
US8785499B2 (en) * 2009-07-10 2014-07-22 University Of Maryland, Baltimore Targeting NAD biosynthesis in bacterial pathogens

Also Published As

Publication number Publication date
EP2928470A4 (en) 2015-12-16
WO2014089378A1 (en) 2014-06-12
JP2016501883A (ja) 2016-01-21
EP2928470A1 (en) 2015-10-14

Similar Documents

Publication Publication Date Title
CA2893318A1 (en) Thienopyridine derivatives for the treatment and prevention of dengue virus infections
AU2010218152B2 (en) Thienopyridine derivatives for the treatment and prevention of Dengue virus infections
JP4109271B2 (ja) 置換されたアリールアシルチオ尿素および関連化合物;ウイルス複製のインヒビター
US20130129677A1 (en) Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections
CN104507481B (zh) 用于治疗、改善或预防病毒疾病的7‑氧代‑4,7‑二氢‑吡唑并[1,5‑a]嘧啶衍生物
CA2850976C (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
AU2008256727A1 (en) Antiviral drugs for treatment or prevention of dengue infection
CA2726985A1 (en) Small molecule inhibitors for the treatment or prevention of dengue virus infection
CN104428301A (zh) Nampt抑制剂
AU2010266570A1 (en) Treatment and prevention of Dengue virus infections
MX2011006514A (es) Compuesto y metodo de uso.
AU2012322698A1 (en) 8 - carbamoyl - 2 - (2,3- di substituted pyrid - 6 - yl) -1,2,3,4 -tetrahydroisoquinoline derivatives as apoptosis - inducing agents for the treatment of cancer and immune and autoimmune diseases
CN103347860A (zh) Nampt抑制剂
CN104271572A (zh) 用作nampt抑制剂的噻唑羧酰胺衍生物
DE102005028077A1 (de) Alkinyl-substituierte Thiophene
JP2008526817A (ja) 新規のピロロジヒドロイソキノリン
WO2010082044A1 (en) Unsaturated bicyclic heterocyclic derivatives as smo antagonists
US20070259911A1 (en) Novel Compounds and Use of Tetrahydropyridothiophenes
CN116261454A (zh) 转录激活蛋白的咪唑并哌嗪抑制剂
AU2015203873A1 (en) Thienopyridine derivatives for the treatment and prevention of dengue virus infections
WO2020177128A1 (zh) 2,6-二氮杂螺[3.4]辛烷类嘧啶-异羟肟酸化合物及其用途
US20090209534A1 (en) Novel compounds and use of tetrahydropyridopyridothiophenes
US20130053396A1 (en) Piperidine and piperazine derivatives as smo antagonists
WO2012109573A1 (en) Substituted thiazoles for use as antiviral agents

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20181206

FZDE Discontinued

Effective date: 20181206